CSL (OTCMKTS:CSLLY) Shares Gap Down - Here's Why

Key Points

• CSL Limited shares gapped down from $64.43 to $61.06 before trading on Friday, closing at $63.67 with a volume of 10,157 shares.
• Analysts have downgraded CSL from a "hold" to a "strong sell" rating, contributing to its bearish market sentiment, despite one analyst maintaining a "strong buy" rating.
• The company's financial ratios indicate a debt-to-equity ratio of 0.50, a quick ratio of 1.12, and a current ratio of 2.46, signaling moderate financial health.

CSL Limited Sponsored ADR (OTCMKTS:CSLLY - Get Free Report) shares gapped down prior to trading on Friday . The stock had previously closed at $64.43, but opened at $61.06. CSL shares last traded at $63.67, with a volume of 10,157 shares trading hands.

Wall Street Analyst Weigh In

Separately, Zacks Research downgraded CSL from a "hold" rating to a "strong sell" rating in a research report on Monday, September 15th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, CSL has a consensus rating of "Moderate Buy".

CSL Stock Down 1.1%

The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.12 and a current ratio of 2.46. The business has a 50-day moving average price of $76.54 and a two-hundred day moving average price of $77.91.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.